Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is
to determine the highest dose of TG02 citrate that can safely be given to patients with
advanced hepatocellular carcinoma.